Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - Further evaluation

Antiviral Therapy

Volumn 14, Issue 7, 2009, Pages 891-898

  Alymova, Irina V ^a   Watanabe, Makiko ^a   Boyd, Kelli L ^a,b   Chand, Pooran ^c   Babu, Y Sudhakara ^c   Portner, Allen ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BCX 2798; HN PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY EPITHELIUM; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; PROTECTION; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS LOAD; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; AZIDES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HEXURONIC ACIDS; HN PROTEIN; HUMANS; MACACA MULATTA; MICE; PARAINFLUENZA VIRUS 1, HUMAN; PREMEDICATION; RESPIROVIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 72249095002     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1420     Document Type: Article

References (20)

1. Karron RA, Collins PL. Parainfluenza Viruses. In DM Knipe, PM Howley (Editors). Fields Virology. 5th ed. Philadelphia: Lippincott/The Williams & Wilkins Co., a Wolters Kluwer Business 2007; pp. 1497-1526.
2. Counihan ME, Shay DK, Holman RC, Lowther SA, Anderson LJ. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001; 20:646-653.
3. Marx A, Török TJ, Holman RC, Clarke MJ, Anderson LJ. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997; 176:1423-1427. (Pubitemid 27518139)
4. Stone-Hulslander J, Morrison TG. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells. J Virol 1997; 71:6287-6295. (Pubitemid 27355281)
5. Yao Q, Hu X, Compans RW. Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces. J Virol 1997; 71:650-656. (Pubitemid 126424277)
6. Crennell S, Takimoto T, Portner A, Taylor G. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol 2000; 7:1068-1074. (Pubitemid 30819713)
7. Takimoto T, Taylor GL, Crennell SJ, Scroggs RA, Portner A. Crystallization of Newcastle disease virus hemagglutininneuraminidase glycoprotein. Virology 2000; 270:208-214. (Pubitemid 30256553)
8. Alymova IV, Taylor G, Takimoto T, et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother 2004; 48:1495-1502. (Pubitemid 38544350)
9. Mascoli CC, Metzgar DP, Larson EJ, Fuscaldo AA, Gower TA. An animal model for studying infection and immunity to and attenuation of human parainfluenza viruses. Dev Biol Stand 1975; 28:414-421.
10. Collier AM, Clyde WA, Jr. Model systems for studying the pathogenesis of infections causing bronchiolitis in man. Pediatr Res 1977; 11:243-246.
11. Murphy TF, Dubovi EJ, Clyde WA, Jr. The cotton rat as an experimental model of human parainfluenza virus type 3 disease. Exp Lung Res 1981; 2:97-109. (Pubitemid 11035732)
12. Tao T, Davoodi F, Cho CJ, et al. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin- neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animal immune to PIV3. Vaccine 2000; 18:1359-1366. (Pubitemid 30017848)
13. Wendt CH, Weisdorf DJ, Jordan MC, et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326:921-926.
14. Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev 2003; 16:242-264.
15. Smith CB, Purcell RH, Bellanti JA, Chanock RM. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966; 275:1145-1152.
16. Murphy BR, Richman DD, Chalhub EG, et al. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun 1975; 12:62-68.
17. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69:39-45. (Pubitemid 41790480)
18. Roche Laboratories Inc. Patient information. Tamiflu (oseltamivir phosphate). (Updated January 2008. Accessed 02 October 2009.) Available from http://www.rocheusa. com/products/tamiflu/ppi.pdf
19. Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/ Vietnam/1203/04 (H5N1). Virology 2008; 374:198-209.
20. Alymova IV, Taylor G, Mishin VP, et al. Loss of the N-linked glycan at residue 173 on human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. J Virol 2008; 82:8400-8410.